⌕
Regencell Bioscience Holdings · RGC · Nasdaq
Tenet 31 · Weak
Compare
$4.72−4.45%At closeTenet 31 · Weak
$4.72−0.22 (−4.45%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Regencell Bioscience Holdings (RGC) Stock Checks

How RGC measures up against value, income, timing, and long-hold tenets. Every criterion shows the number as of the last close and the pass rule. Always free.

Sources Company filings and computed by Tenet Filings and TenetScreens as of How we compute thisNot investment advice

The tenets below and the 0-100 Tenet Score on this report are two separate computations: each tenet runs its own criteria and its own pass rule, while the score is a percentile composite reported as one of four verdict words (Strong, Solid, Mixed or Weak).

0 / 17 qualify todayas of close, Nov 13, 2026 · computed nightly from our fundamentals DB; point-in-time auditable.
QUALIFIES
0
meet every gate today
BORDERLINE
0
within one input of the gate
FAILS
3
miss at least one gate
UNKNOWN
14
insufficient data to judge
Buffett Qualitydurable moat
✕ Fails
FailsROE ≥ 15%−128.5% · ≥ 15.0%
Unknown — no dataGross margin ≥ 40%— · ≥ 40.0%
Unknown — no dataNet margin ≥ 15%— · ≥ 15.0%
PassesDebt/equity ≤ 0.50.00 · ≤ 0.50
FailsGrowing FCF (multi-yr)Free cash flow was negative in fiscal 2026.no · > 0
Decided by the pass rule for Buffett Quality.
The pass rule for Buffett Quality is what decides that verdict, and it is not restated here. 2 of 5 carry no data.Buffett Quality under The screens ›Today's Buffett Quality list ›
FailsReturn on assets positive−79.4% · > 0
FailsOperating cash flow positive−$7.7M · > 0
FailsReturn on assets improving−62.3% → −79.4%
PassesEarnings backed by cash (CFO > net income)−$7.7M vs −$11.7M
FailsLeverage falling (long-term debt / assets)We hold no record of long-term debt as a share of assets for both years for this company, so this signal could not be measured. It still scores 0 under this module's conservative rule (a point is never awarded without evidence), and it is not counted as one of the signals we were able to measure.no
PassesCurrent ratio improving7.39 → 10.77
PassesNo share dilution (≤ +2%)+0.0%
FailsGross margin expandingThis company files on a financial-statement template with no gross-profit line (banks and insurers do not report one), so gross margin could not be measured for either year. It still scores 0 under this module's conservative rule (a point is never awarded without evidence), and it is not counted as one of the signals we were able to measure.no
FailsAsset turnover improving0.00 → 0.00
Decided by the pass rule for Piotroski F-Score.
The pass rule for Piotroski F-Score is what decides that verdict, and it is not restated here. 2 of 9 carry no data.Piotroski F-Score under The screens ›Today's Piotroski F-Score list ›
Unknown — no dataROIC ≥ 15%— · ≥ 15.0%
Unknown — no dataNet debt/EBITDA ≤ 3×— · ≤ 3.0×
Unknown — no dataAltman Z ≥ 3 (safe zone)— · ≥ 3.00
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 3 checks below carry data.Munger Compounders under The screens ›Today's Munger Compounders list ›
FailsEBIT > 0−$11.7M · > 0
Unknown — no dataEarnings yield EBIT/EV ≥ 6%— · ≥ 6.0%
Unknown — no dataReturn on capital ≥ 25%— · ≥ 25.0%
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 3 checks below carry data. The pass rule for Magic Formula is not published separately on the methodology page.About this screen ›Today's Magic Formula® list ›
PassesSize: market cap ≥ $2B$2.4B · ≥ $2.0B
PassesCurrent ratio ≥ 210.77 · ≥ 2.00
FailsPositive EPS 7yWe hold no record of earnings per share for fiscal 2019, and this company's net income and earnings per share disagree in sign in other years, so that year is left out and this test covers the 7 fiscal years we can judge.2y
FailsPays a dividend$0.00 · > 0
Unknown — no dataEPS growth ≥ 3%/yr— · ≥ 3.0%
Unknown — no dataP/E ≤ 15— · ≤ 15.00
Unknown — no dataP/E × P/B ≤ 22.5— · ≤ 22.50
Decided by the pass rule for Graham Defensive.
The pass rule for Graham Defensive is what decides that verdict, and it is not restated here. 3 of 7 carry no data.Graham Defensive under The screens ›Today's Graham Defensive list ›
Unknown — no dataPEG < 1 (hist. growth)— · < 1.00
Unknown — no dataEPS growth 10–30%— · 10.0%–30.0%
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 2 checks below carry data.Lynch GARP under The screens ›Today's Lynch GARP list ›
FailsPays a dividend$0.00 · > 0
Unknown — no dataYield in a healthy band (not a yield trap)0.0% · 1.0%–8.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataEarnings payout not stretched— · ≤ 75.0%
Unknown — no dataBalance sheet can sustain the payout— · ≤ 4.0×
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 5 checks below carry data. The pass rule for Income & Dividend Safety is not published separately on the methodology page.
FailsPays a dividend$0.00 · > 0
Unknown — no dataAnnual dividend raised 10+ years running (Aristocrat ≥25, King ≥50)— · ≥ 10.00
Unknown — no dataNo dividend cut in the last 5 years—
Unknown — no data5-year dividend growth ≥ 5%/yr— · ≥ 5.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataPayout not stretched— · ≤ 75.0%
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 6 checks below carry data.Dividend Growth under The screens ›Today's Dividend Growth list ›
FailsReturn on invested capital ≥ 15% in 4+ of the last 5 years0 of 5
Not scored: see the reason belowRevenue compounding ≥ 8%/yr over 5 yearsFive-year revenue history is incomplete in our data, so the compounding rate can't be computed yet.— · ≥ 8.0%
FailsNot diluting: diluted share count flat-to-down (≤ +1%/yr)4.5% · ≤ 1.0%
Not scored: see the reason belowFree cash flow margin ≥ 12%Free-cash-flow margin isn't derivable yet from the statements we have on file.— · ≥ 12.0%
Not scored: see the reason belowEarnings backed by cash (operating cash flow ≥ net income)A loss year makes cash-vs-earnings unreadable: the ratio inverts over negative net income, so it is not scored (never counted against).— · ≥ 1.00
Reading: does not hold. Not a gate checkDisciplined buybacks: actively reducing the share count (bonus)reading, not a gate check4.5%
Verdict Unknown for this set.
Verdict Unknown for this set. 2 of 5 checks below carry data. Lines marked as readings are published beside the checks and are not gate checks.Quality Compounder under The screens ›Today's Quality Compounder list ›
Unknown — no dataOff its 52-week high by 8–35% (a dip, not a collapse)— · 8.0%–35.0%
Unknown — no dataDip within its own normal pullback band—
Unknown — no dataNot past where its dips have historically recovered from—
Unknown — no dataA dip in an uptrend (above a rising 200-day)—
Unknown — no dataHigher-low structure still intact—
Unknown — no dataClear of the earnings blackout (more than 5 days out)— · > 5.00
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 6 checks below carry data. The pass rule for Drawdown Context is not published separately on the methodology page.
Unknown — no dataA bullish MACD cross within 10 sessions— · ≤ 10.00
Unknown — no dataReclaimed a rising 50-day EMA—
Unknown — no dataPrinted a higher low—
Unknown — no dataA volume thrust on the turn (≥ 1.2× normal)— · ≥ 1.20
Unknown — no dataReversal signals fired: 3 of 4 (MACD·MA·HL·Vol)— · ≥ 3.00
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 5 checks below carry data. The pass rule for Reversal Evidence is not published separately on the methodology page.
Unknown — no dataIn the cheap half of its own 5-year valuation range—
Unknown — no dataEarnings estimates not being cut—
Unknown — no dataReturns on capital not deteriorating—
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 3 checks below carry data. The pass rule for Not-a-Value-Trap Gate is not published separately on the methodology page.
Unknown — no dataOperating profit is positive— · > 0
Unknown — no dataReturn on invested capital ≥ 10%— · ≥ 10.0%
Unknown — no dataA solvent balance sheet (Altman Z ≥ 1.8, net debt/EBITDA ≤ 4)—
Unknown — no dataQuality score ≥ 50— · ≥ 50.00
Unknown — no dataRevenue growing over 5 years— · > 0
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 5 checks below carry data. The pass rule for Quality Floor is not published separately on the methodology page.
A research signal from published criteria, not a recommendation.
Unknown — no dataDrawdown context—
Unknown — no dataReversal evidence—
Unknown — no dataTrap gate—
Unknown — no dataQuality floor—
Invalidation level (structure break) not yet computable—
Verdict Unknown for this set.
Verdict Unknown for this set. No price factors yet: the timing receipts populate after the nightly engine runs.Qualified Dip under The screens ›Today's Qualified Dip list ›
Unknown — no dataTrading above its 50-day average—
Unknown — no dataTrading above its 200-day average—
Unknown — no data50-day average above the 200-day (uptrend stack)—
Unknown — no data50-day average sloping up— · > 0
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 4 checks below carry data. The pass rule for Trend Alignment is not published separately on the methodology page.
Unknown — no data3-month return in the top half of the universe— · ≥ 0.50
Unknown — no data12-minus-1 momentum in the top half of the universe— · ≥ 0.50
Unknown — no dataRelative strength vs the S&P 500 improving— · > 0
Unknown — no dataEarnings estimates being revised up—
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 4 checks below carry data. The pass rule for Relative Strength is not published separately on the methodology page.
Unknown — no dataMACD above its signal line—
Unknown — no dataBack above the 50-day on a fresh cross (≤10 sessions)—
Unknown — no dataHigher high and higher low (stair-stepping up)—
Unknown — no dataA volume thrust on the move (≥ 1.2× normal)— · ≥ 1.20
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 4 checks below carry data. The pass rule for Momentum Trigger is not published separately on the methodology page.
Average daily swing—
Volatility band width—
Distance from its 52-week high—
Every verdict is auditableEach criterion shows the number as of the last close and the pass rule side by side: a receipt, not a rating. Several of these screens publish their rule in full under The screens; each row links to its own section where there is one.
Unknown ≠ failAn “— Unknown” verdict means the inputs were insufficient: context, not a signal, and never counted as a fail.

How many investing rule sets does Regencell Bioscience Holdings pass?

Regencell Bioscience Holdings qualifies on 0 of 17 rule sets as of 2026-11-13, with 0 borderline and 3 failing.

Does Regencell Bioscience Holdings meet the Graham Defensive criteria?

Regencell Bioscience Holdings fails the Graham Defensive rule set as of 2026-11-13.

Does Regencell Bioscience Holdings meet the Buffett Quality criteria?

Regencell Bioscience Holdings fails the Buffett Quality rule set as of 2026-11-13.

Computed from our fundamentals DB; historical-CAGR PEG basis for Lynch. Research, not investment advice. Tenet's rulesets are independently developed from publicly available sources, and Tenet is not affiliated with, sponsored by, endorsed by or otherwise associated with any referenced investor or trademark owner. Full notice. MAGIC FORMULA is a trademark of MagicFormulaInvesting.com LLC.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.